Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease
NCT06236672
Completed
The overall objective of this study is to compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist compared with adding basal insulin for patients with type 2 diabetes and chronic kidney disease, already treated with an sodium-glucose cotransporter-2 inhibitor and not currently reaching target glycemic control. All sociodemographic information and clinical variables will be retrieved from the LMC Diabetes Registry.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: LMC Diabetes & Endocrinology Ltd., Toronto, Ontario
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Register for Updates
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
NCT02787551
Completed
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change. Secondary Objectives: To compare the overall efficacy and safety of the insulin glargine/lixisenatide FRC to GLP-1 RA on top of metformin (with or without pioglitazone, with or without sodium-glucose co-transporter 2 \[SGLT2\] inhibitor) in participants with type 2 diabetes. To evaluate safety, efficacy... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2022
Locations: Investigational Site Number 8400064, Birmingham, Alabama +123 locations
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus
NCT02229227
Completed
This Phase IIIb, randomized, open-label, parallel group, active control, multicenter, treat to-target study of 26 weeks' treatment duration will evaluate the efficacy and safety of once-weekly albiglutide as replacement of prandial insulin in subjects with type 2 diabetes mellitus (T2DM) failing to achieve adequate glycemic control on their current basal bolus insulin regimen (with or without metformin). Approximately 794 subjects will be randomly assigned in a 1:1 ratio to 1 of 2 treatment grou... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/13/2020
Locations: GSK Investigational Site, Searcy, Arkansas +157 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
NCT02465515
Completed
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2019
Locations: GSK Investigational Site, Birmingham, Alabama +607 locations
Conditions: Diabetes Mellitus
Register for Updates
Incretin-based Drugs and Acute Pancreatitis
NCT02476760
Completed
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of acute pancreatitis (AP) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/01/2016
Locations: Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec
Conditions: Diabetes Mellitus, Type 2
Register for Updates
Incretin-based Drugs and the Risk of Heart Failure
NCT02456428
Completed
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone or in combination with other anti-diabetic drugs are associated with an increased risk of heart failure (HF) compared to other combinations of oral hypoglycemic agents (OHA). The investigators will carry out separate population based cohort studies using administrative health databases in six jurisdictions in Canada, the US and the UK. Cohorts will be defined by the initiati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2016
Locations: Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec
Conditions: Type 2 Diabetes Mellitus
Register for Updates
Incretin-based Drugs and Pancreatic Cancer
NCT02475499
Completed
The purpose of this study is to determine whether incretin-based drugs (used to treat type 2 diabetes) taken either alone in or combination with other anti-diabetic drugs are associated with an increased risk of pancreatic cancer (PC) compared to sulfonylureas. The investigators will carry out separate population based cohort studies using administrative health databases in five jurisdictions in Canada, the US, and the UK. Cohorts will be defined by the initiation of a new anti-diabetic drug wh... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2016
Locations: Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec
Conditions: Diabetes Mellitus, Type 2
Register for Updates